|Bid||3.6900 x 800|
|Ask||4.6000 x 4000|
|Day's Range||3.6100 - 4.0738|
|52 Week Range||3.3400 - 22.0000|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.00|
NEW YORK, May 21, 2019 -- Pomerantz LLP is investigating claims on behalf of investors of Ra Medical Systems, Inc. (“Ra Medical” or the “Company”) (NYSE: RMED). Such investors.
Ra Medical Systems, Inc. (RMED) today announced that Dr. Mohammad Ansari will present DABRA as a treatment for critical limb ischemia (CLI) during a scientific case review May 21 at the SCAI annual meeting in Las Vegas. “The unique DABRA catheter and laser system is a highly effective frontline therapy for peripheral artery disease (PAD) that provides my patients excellent results, shorter rehabilitation time, and shorter hospitalizations,” said Dr. Ansari, Director of the Cardiac Cath Lab, Structural Heart & Interventional Cardiology Research and Assistant Professor, Division of Cardiology, at Texas Tech University Health Sciences Center. The presentation, titled, “Innovation Update: Redefining Excimer Laser Photoablation – A Case Review Demonstrating the Utility and Versatility of DABRA as a Front Line Therapy for CLI,” will take place on Tuesday, May 21 at 3:50 pm in the Innovation Showcase Theater.
NEW YORK, May 17, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ra Medical Systems, Inc..
Glancy Prongay & Murray LLP announces the continuation of its investigation on behalf of Ra Medical Systems, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws.
Ra Medical Systems, Inc. (RMED) filed a complaint today in the United States District Court for the Southern District of California alleging Mr. Uri Geiger, Chairman of Strata Skin Sciences, Inc. and managing partner of Accelmed (Strata’s majority stockholder), undertook a campaign of false, misleading, and disparaging statements to Ra Medical’s financial partners and potential investors before, during, and after Ra Medical’s initial public offering. Ra Medical believes these false statements constituted intentional interference with Ra Medical’s contractual relations and prospective economic relations, as well as trade libel. In addition, Ra Medical alleges that the statements breached the non-disparagement provision of a prior settlement agreement to which Strata was expressly bound.
NEW YORK, May 16, 2019 -- Pomerantz LLP is investigating claims on behalf of investors of Ra Medical Systems, Inc. (“Ra Medical” or the “Company”) (NYSE: RMED). Such.
Ra Medical Systems, Inc. (RMED) today announced its investment to support high quality patient care in Office Interventional Suites through its Platinum Partnership, the highest level of commitment, with the Outpatient Endovascular and Interventional Society (OEIS). Ra Medical Systems was recognized for its shared vision and financial contribution at the OEIS 6th annual national meeting in St. Petersburg, FL. “We believe patient care through Office Interventional Suites (OIS) is the future of endovascular medicine, and we share OEIS’ mission of innovation, evidence-based outcomes, and patient safety,” said Dean Irwin, CEO, Ra Medical Systems.
Glancy Prongay & Murray LLP announces an investigation on behalf of Ra Medical Systems, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws.
Law Offices of Howard G. Smith announces an investigation on behalf of Ra Medical Systems, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws.
NEW YORK, May 08, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against Ra Medical Systems, Inc. (NYSE: RMED) on behalf of Ra Medical stockholders..
Ra Medical Systems, Inc. announces that it will report first quarter 2019 financial results after market close on Monday, May 13, 2019. Ra Medical management will hold an investment community conference call at 4:30 p.m.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Ra Medical Systems, Inc.'s (NYSE:RMED) most recent earnings announcement in December 2018 indica...
Ra Medical Systems, Inc. today announced the schedule of key DABRA Excimer Laser Atherectomy events at the upcoming Charing Cross International Symposium in London April 16–18.
Introduces new integrated commercial strategy to support physician adoption of the DABRA laser system and build long-term customer relationshipsConference call begins at 4:30 pm Ea
Ra Medical Systems, Inc. , today announced study results from Athar Ansari, MD, Director of the California Heart & Vascular Clinic, who stated, “DABRA is fundamentally changing the way I practice medicine.” Dr.
Ra Medical Systems, Inc. announces that it will report 2018 fourth quarter and full year financial results after market close on Thursday, March 14, 2019. Ra Medical management will hold an investment community conference call at 4:30 p.m.
The study results were overwhelmingly positive, given the inclusion of a challenging sample of patients, all Rutherford class 4 to 6 with a high presence of calcium (80% of lesions had moderate to severe calcification) and 93% median lesion stenosis. “The results of this study are extremely promising and demonstrate the positive clinical outcomes we have seen with DABRA,” said Dr. Kondur, Chair, Division of Cardiology, Garden City Hospital/MSU and Associate Program Director, Interventional Cardiology Fellowship Program, DMC Harper University Hospital, Wayne State University.
Ra Medical Systems, Inc. (RMED), a medical device company focusing on commercializing excimer laser systems to treat tough vascular and dermatological diseases, announces that CEO Dean Irwin will present at the 11th Annual Biotech Showcase on January 8, 2019, in San Francisco. Mr. Irwin will present an overview of Ra Medical’s business, technology and strategic growth objectives, including the commercialization of its excimer laser system, DABRA™, which is FDA-cleared to cross chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease.
Ra Medical Systems, Inc.'s (NYSE:RMED): Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. Read More...
Mr. Fogarty brings over two decades of medical device leadership and commercialization experience to Ra Medical Systems and will oversee all aspects of the Company's commercialization efforts, which include the sales and marketing of its proprietary excimer laser systems that treat tough vascular and dermatological diseases. “Over the years, Tom has demonstrated a proven track record leading both early-stage companies and large corporations through commercialization and sales growth,” said Dean Irwin, Chief Executive Officer, Ra Medical Systems.